This medication is a HER2-targeted antibody and microtubule inhibitor, prescribed as a single medicine for the treatment in patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. .  

None.

IV- The recommended dose is 3.6 mg/kg every 3 weeks (21-day cycle).

It comes as powder for injection (diluted with fluid), to be administered by a healthcare provider into the vein.

• Caution should be exercised in patients with history of liver or heart problem, any allergy, who are taking other medications, elderly, children, during pregnancy and breastfeeding.
• Ado-trastuzumab emtansine should not be administered at doses greater than 3.6 mg/kg.
• Should not substitute for or with trastuzumab.
• Monitor platelet counts prior to each dose of this drug administration.
• Perform HER2 testing while taking this medication.
• Discontinue this medication in patients diagnosed with interstitial lung disease or pneumonitis.

•   Serious Effects : Lung problems, injection site reactions, nerve damage, heart damage, embryo-fetal toxicity.
•   Most Common : Fatigue, nausea, muscle and bone pain, decrease in platelet counts, headache, increased level of liver enzymes and constipation.
•   Miscellaneous : Tiredness, liver problems, nerve problems.

Avoid excess dosage.

Store vials in a refrigerator at 2°C to 8°C.